Is treatment with curative intent the ultimate goal?
Is intensive chemotherapy the antileukaemic standard of care?
How should MRD assessment inform treatment decisions?
Pursuing long-term survival in the real world
Learning Objectives & Overview
High-risk* acute myeloid leukaemia (AML) has a poor prognosis and remains a therapeutic challenge.1 In this sponsored Symposium, recorded at the 5th Annual Meeting of the International Academy for Clinical Haematology, six leading experts present and discuss key aspects of high-risk AML treatment, including the importance of measurable residual disease, and clinical/real-world evidence for the use of Vyxeos Liposomal (Daunorubicin 44 mg / Cytarabine 100 mg)2–4
*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
After watching this activity, participants should be better able to:
- Describe the key treatment goals and factors influencing treatment decisions in high-risk* AML
- Discuss the role of measurable residual disease in the management of high-risk* AML
- Review the clinical and real-world evidence on the use of Vyxeos Liposomal (CTX-351) for the treatment of high-risk* AML
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to email@example.com
- Granfeldt Østgård LS, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641–9.
- Lancet JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.
- Chiche E, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176–184.
- Guolo F, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10:96.